- Home
- PMEC vs VRCA Comparison
PMEC vs VRCA Comparison
Compare PMEC & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | VRCA |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 87.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PMEC | VRCA |
|---|---|---|
| Price | $0.72 | $6.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 188.1K | 125.6K |
| Earning Date | 01-01-0001 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.60 | $0.39 |
| 52 Week High | $2.44 | $9.82 |
Technical Indicators
Market Signals| Indicator | PMEC | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 51.31 |
| Support Level | $0.60 | $5.22 |
| Resistance Level | $1.11 | $6.44 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 24.72 | 70.51 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.